GSK-3β Inhibitor II 19296 1 and 10 μM) improves

1 and 10 μM) improves cell survival of rat neonatal cardiomyocytes compared to vehicle-treated cells

CDP 840 at doses of 10 and 30 mg/kg increased the phosphorylation of cAMP response element binding protein (pCREB) in the hippocampus (by 36 and 55%

C4H6O4/c1-15-20(18

Smiles: CC(C/C(/C)=C\C(CO)/C=C(\C)/C=C/C(O)C(C)(C)C1=CC(=O)C([C@@H]2O[C@@H](C[C@H](O)[C@H]2O)CO)=C(O)O1)CCCCCC

InChiKey: CBOJBBMQJBVCMW-MVNLRXSJSA-N

GSK-3β Inhibitor II 19296 1 and 10 μM) improvesIC50: 390 nM for GSK 3 GSK 3 Inhibitor II is a GSK 3 inhibitor. Glycogen Synthase Kinase 3 (GSK 3), a protein serine kinase, is implicated in the hormonal control of various regulatory proteins. A number of substrates have been identified, which implicates GSK 3 in the regulation of several physiological processes. Moreover, it has been reported that compounds that specifically inhibit GSK 3 activity may be useful in the treatment of diabetes. In